Evidence map›Paper›PMID 41984171›Full record

ArticleJournal of medicinal chemistry2026

Preclinical Evaluation of 5T4-Targeted [

Yuanyuan Liang, Xiangyun Li, Hui Liang, Tao Wu, Yao Huang, Shoumei Liu, Xia Yang, Rui Luo, Fanxin Ma, Ying Huang and 2 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuanyuan LiangNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Xiangyun LiNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Hui LiangNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Tao WuNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Yao HuangNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Shoumei LiuNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Xia YangInstitute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang 621900, China.
Rui LuoDepartment of Nuclear Medicine, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.
Fanxin MaSound Biopharmaceuticals Co., Ltd., Tianfu International Bio-Town, Huigu Dong Second Road 8, Chengdu, Sichuan 610200, China.
Ying HuangSound Biopharmaceuticals Co., Ltd., Tianfu International Bio-Town, Huigu Dong Second Road 8, Chengdu, Sichuan 610200, China.
Xiaoan LiNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.ORCID 0009-0006-8293-8845
Yan ZhouNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, Sichuan 621000, China.ORCID 0009-0007-1673-9108

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The oncofetal antigen 5T4 is highly expressed in colorectal cancer (CRC), making it a promising theranostic target. In this study, we developed the diagnostic tracer [

Indexed as

Antibodies, MonoclonalColorectal NeoplasmsLutetiumPositron-Emission TomographyRadioisotopesRadiopharmaceuticalsTerbiumZirconiumAnimalsCell Line, TumorFemaleHumansMiceMice, Inbred BALB CMice, NudeTissue DistributionAntibodies, MonoclonalLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsTerbiumZirconiumZirconium-89

Identifiers

PMID41984171
PMCPMC13182767

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.